BIOMAT Database Logo BIOMAT Database Logo

Loperamide: a new antidiarrheal agent in the treatment of chronic diarrhea. 1976

J T Galambos, and T Hersh, and S Schroder, and J Wenger

Twenty-seven patients with chronic diarrhea due to Crohn's disease, ulcerative colitis, short bowel syndrome, and idiopathic (functional) causes participated in a multiphase study (open, double blind, and long term open) of loperamide HCl, a new single entity, oral antidiarrheal agent. In the open phase of the study, loperamide effectively relieved symptoms of diarrhea in 21 of 27 patients. The average number of stools dropped from eight in the initial relapse period to two stools after 1 month of treatment (P = 0.0001). Efficacy was confirmed in the double blind and long term open phases of the study. Four patients who were not relieved while on therapy had discontinued the drug because of abdominal cramping. No other side effects attributable to the drug were observed. Loperamide has been found to be a safe and effective agent for the treatment of chronic diarrhea.

UI MeSH Term Description Entries
D008139 Loperamide One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally. Imodium,Loperamide Hydrochloride,Loperamide Monohydrochloride,R-18553,Hydrochloride, Loperamide,Monohydrochloride, Loperamide,R 18553,R18553
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010880 Piperidines A family of hexahydropyridines.
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J T Galambos, and T Hersh, and S Schroder, and J Wenger
Loperamide, a new antidiarrheal agent in the treatment of chronic diarrhea.
July 1978, Schweizerische medizinische Wochenschrift,
J T Galambos, and T Hersh, and S Schroder, and J Wenger
Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 7: Clinical investigation. Efficacy and safety of loperamide in patients with severe chronic diarrhea.
October 1974, Arzneimittel-Forschung,
J T Galambos, and T Hersh, and S Schroder, and J Wenger
[Loperamide in the treatment of chronic diarrhea].
January 1979, Polski tygodnik lekarski (Warsaw, Poland : 1960),
J T Galambos, and T Hersh, and S Schroder, and J Wenger
Treatment of diarrhea in irritable colon, including preliminary observations with a new antidiarrheal agent, diphenoxylate hydrochloride (Lomotil).
January 1961, The American journal of gastroenterology,
J T Galambos, and T Hersh, and S Schroder, and J Wenger
Treatment of diarrhea in irritable colon, including preliminary observations with a new antidiarrheal agent, diphenoxylate hydrocloride (Lomotil).
January 1961, The American journal of gastroenterology,
J T Galambos, and T Hersh, and S Schroder, and J Wenger
[Antidiarrheal drugs for chronic diarrhea].
November 2013, Deutsche medizinische Wochenschrift (1946),
J T Galambos, and T Hersh, and S Schroder, and J Wenger
Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 5: the pharmacokinetics of loperamide in rats and man.
October 1974, Arzneimittel-Forschung,
J T Galambos, and T Hersh, and S Schroder, and J Wenger
Potent Inhibition of hERG Channels by the Over-the-Counter Antidiarrheal Agent Loperamide.
December 2016, JACC. Clinical electrophysiology,
J T Galambos, and T Hersh, and S Schroder, and J Wenger
Loperamide, an antidiarrheal agent, induces apoptosis and DNA damage in leukemia cells.
January 2018, Oncology letters,
J T Galambos, and T Hersh, and S Schroder, and J Wenger
In vivo antimotility and antidiarrheal activity of lidamidine hydrochloride (WHR-1142A), a novel antidiarrheal agent. Comparison with diphenoxylate and loperamide.
January 1978, Arzneimittel-Forschung,
Copied contents to your clipboard!